ALK and liver cancer: Prioritized drugs for liver cancer could be clustered into four different classes of tyrosine kinase inhibitors: (i) JAK inhibitors (i.e., sorafenib, vandetanib, erlotinib, and lapatinib), (ii) ALK inhibitors (i.e., lorlatinib), (iii) BCR–Abl (i.e., nilotinib, dasatinib, and imatinib), and (iv) and EGFR inhibitors (i.e., afatinib).33 In addition, we found MEK kinase inhibitors, specifically trametinib and cobimetinib.